I believe big pharma has their eyes on APHB. They actually suck in their methods of acquiring/joint venturing with sub pharma....APHB will incur all the financial hardships trying to prove their product works....selling shares, borrowing money etc then...if and only if its successful big pharma will make an offer to capture that drug. Pfizer just cut their R/D on cancer drugs saying its too expensive to fund so a trend is beginning with drug companies.... "Trump saying drugs too costly"
So I think you will see the burden change to the sub bio pharma developing on the shareholders backs then ultimately ....???!!! if it works get bought by the big boys!!
As a APHB stock holder...I see this happening in 2018